Scientific Advisory Services Team
Lauren E. Black, PhD
An ex-FDA reviewer, Lauren Black is now a Distinguished Scientist at Charles River with more than 25 years of experience in drug development, focusing on accelerated translation to Phase I/II clinical trials.
She works mainly at the first in human (FIH) stage - in high risk diseases using novel products. Before Charles River, Dr. Black was a reviewing pharmacologist in the FDA’s CDER and CBER, during which time she assessed preclinical data, worked on many FDA guidances, and represented FDA externally on oligonucleotides, safety pharmacology, choice of relevant species, and utilization of PAD as the response index for setting human safety margins. She was a founding co-author of FDA’s Human Start Dose guidance. As a specialist in biologic therapies and targeted agents, she was elected to serve in BIO’s BioSafe committee in leadership roles, resulting in a white paper on selective uses of large animals for human risk assessment. She sits on several government, academic, and industry advisory panels discussing in vitro toxicology, portfolio prioritization, technology transfer/capitalization, and regulatory strategy. Dr. Black received her BS from Carnegie Mellon University and PhD in pharmacology from the Virginia Commonwealth University School of Medicine, where she researched GPCRs.
- Two years at NIH, 11 years at FDA, and 15 years at Charles River
- Specialist in translational research for all products, especially in high risk diseases
- Focus on immunomodulatory drugs and biologics, vaccines and cell/gene therapies, including specialized combination products and novel delivery technology
- Expert on regulatory programs, in vitro concept through clinical trial preparation
- Nonclinical safety and risk assessment
- Collaborative design of lean programs, including in animal models of disease
- Communication strategy with FDA
Samuel S. Chuang, PhD
An experienced scientist, Sam Chuang collaborates with pharmaceutical and biotechnology companies worldwide, advising on drug development programs and study designs and monitoring nonclinical regulatory packages.
He provides scientific and regulatory expertise covering a variety of drug classes (small to large molecule), therapeutic areas, routes of administration, and animal species. He manages multidisciplinary research teams for multiple drug development programs from target identification and drug discovery to preclinical safety programs. Sam is a member of the Society of Toxicology.
- Over 20 years of academic, biotechnology and preclinical CRO research experience, with 16+ years drug development experience
- Project toxicologist for new chemical entities, new biological entities, and new vehicles
- Design, management, scientific and regulatory review, and reporting at all stages of candidate development
David F. Fischer, PhD
Executive Director of Discovery Sciences, David Fischer joined Charles River through the acquisition of BioFocus.
He has led numerous early stage drug discovery programs in rare and orphan disease indications. He brings expertise in complex and primary cell-based assays, including iSPC and hESC stem cell models and human primary cell models. David holds a degree in Chemistry and a PhD in molecular Genetics, both from Leiden University.
- Focus areas include cystic fibrosis, Huntington’s disease, ALS, Usher III Syndrome, Duchenne muscular dystrophy, and neurodegenerative disorders (Alzheimer’s and Parkinson’s disease.)
- During his postdoctoral fellowships at the Netherlands Institute for Neuroscience in Amsterdam (an Institute of the Royal Netherlands Academy of Arts and Sciences) and the Free University Amsterdam, he focused on Alzheimer’s and Huntington’s Disease and mentored two graduate students, at the University of Amsterdam and at Leiden University
- Over 50 patent applications and peer-reviewed papers
Joseph A. Francisco, Ph.D.
Senior Director, Scientific Advisory Services
Joe Francisco provides scientific and regulatory guidance on the nonclinical development of small molecule drugs and biotechnology-derived therapeutics.
Earlier in his career as a Program Advisor within Charles River, he provided strategic and tactical guidance to a diverse array of domestic and international pharmaceutical and biotechnology companies, ranging from small virtual companies to large multinational organizations. Joe also has experience as an independent consultant, working with small biotechnology companies to establish preclinical strategies to support the development of novel therapeutics.
- Over 25 years of experience in drug development in the CRO and biotech industries and as an independent consultant
- Significant experience in the nonclinical development of small molecule, protein therapeutics, and cell therapies
- Expert understanding of the strategic and tactical aspects of successful preclinical drug development programs: program design, execution, and leadership
- Proven leadership in coordinating, integrating, and leading multidisciplinary teams
- Member and Councilor (2017-2020) of the American College of Toxicology (ACT)
- Member of SOT, including serving as Councilor of the Biotechnology Specialty Section (2015-2017)
- Chair of the Charles River Biotech Symposium Program Committee (2014-present)
Pete Gaskin, PhD, ERT, MTOPRA
Pete Gaskin is a senior director of scientific advisory services who is experienced in biotechnology and pharmaceutical drug development.
With expertise in toxicology, pharmacology, pharmacokinetics, and pharmacodynamics, he has a proven track record for transitioning drug candidates from research into development. His diverse scientific knowledge base guides our clients’ nonclinical development and advice for strengthening and/or accelerating nonclinical programs. Pete specializes in multiple therapeutic areas, including cancer, inflammation, neurology, cardiovascular, and metabolic diseases.
- More than 25 years of life science, and 18+ years of pharmaceutical program management and consulting experience
- Management of early development programs to clinical proof-of-concept and leadership of nonclinical programs to market
- Development of biologics, proteins/peptides, oligonucleotides, gene and cell therapy and small molecules
- Writing and reviewing nonclinical regulatory documentation and interacting with regulatory authorities
- Member of the British and European Societies of Toxicology and the American College of Toxicology
- UK and European Registered Toxicologist and a member of TOPRA
- Invited speaker at scientific meetings, and presenter at universities and drug development courses
Sarah Gould, PhD
Senior Principal Scientific Advisor
Sarah Gould is a senior principle scientific advisor with extensive experience (20 + years) in biotech, pharma and as a consultant.
She has a proven track record of delivering toxicology and safety pharmacology programs, individual studies and regulatory documents (IND, IMPD, CTD) for both small and large molecules (proteins, peptides, mAbs, virus vectors) along the development pipeline and has supported over 100 submissions. Sarah has interacted with various health authorities, including FDA, EMA, PMDA, as well as individual European authorities and emerging markets.
- Deep expertise in various therapeutic areas and modalities including vaccines/adjuvants, oncology including oncolytics and miRNA, diabetes including obesity, immunology, cardiovascular, neuroscience, anti-infectives and toxicology evaluations of chemicals
- Presented, organized and chaired toxicology meetings including at SOT, Eurotox, HESI, DIA and Biosafe
- Involved in international scientific collaborations: HESI (vice president- safety of adjuvants; concordance project) and IMI projects (EFPIA rep)
- Contributory author to regulatory guidelines documentation including safety assessment of process residues/contaminants in vaccines (EVM re: TTC, 2012); WHO vaccine guideline (2013)
- Published several scientific papers in peer reviewed journals and co-authored a book chapter titled “vaccine toxicology: nonclinical predictive strategies” and is also an ad hoc reviewer for peer reviewed journals
Jos Mertens, PhD, DABT
Senior Principal Scientific Advisor
Senior principal scientific advisor Jos Mertens is a board-certified toxicologist with more than 22 years of CRO-experience in nonclinical development of small and large molecules by pharmaceutical and non-pharmaceutical industries.
He primarily advises clients and internal stakeholders on nonclinical program and study designs for biopharmaceuticals and small molecules under development for a wide variety of therapeutic areas.
- Four years of postdoctoral experience at the Division of Pharmacology and Toxicology of the College of Pharmacy at the University of Texas at Austin
- More than 20 years as nonclinical CRO toxicologist and study director for nonclinical studies
- Focus on IND and post-IND phases for human and veterinary pharmaceuticals and mode of action and data registration packages for agrochemicals
- Certified in General Toxicology by the American Board of Toxicology
- Ad-hoc reviewer for peer-reviewed journals
- Member of Society of Toxicology (Biotechnology, Carcinogenesis, and Immunotoxicology Specialty Sections)
- Member of the American College of Toxicology, including service on the organization’s council and Award, Membership and Program committees
Christopher L. Murriel, PhD
Principal Scientific Advisor
Christopher Murriel is a Principal Scientific Advisor in Discovery Oncology with extensive experience and expertise in oncology drug discovery.
Prior to Charles River, Dr. Murriel was an Associate Director in the Department of Research at OncoMed Pharmaceuticals where he directed preclinical study efforts aimed at determining the efficacy, MoA, and pharmacodynamic effects of OncoMed’s pipeline of small molecule and biologic research and development programs involving cancer stem cell, anti-angiogenic, immuno-oncology, and autoimmune diseases. In addition, Chris has diverse expertise in developing cancer mouse models including PDX, syngeneic, genetically engineered, and humanized models, as well as those involved in autoimmune disease research.
- 20+ years of life science and over 12 years of biotechnology industry-related research experience in cancer biology, immuno-oncology, autoimmune disease, and cardiovascular research
- Expertise in establishing, utilizing, and managing pre-clinical in vivo studies to support biologic and small molecule therapeutics development: relevant models include syngeneic, genetically engineered, patient-derived (PDX), humanized and autoimmune disease mouse model platforms
- Demonstrated accomplishment of major contributions towards advancing numerous biologics and small molecule therapeutics against WNT, NOTCH, R-spondin, TIGIT, and GITRL-Fc from discovery to IND-enabling studies
- Experience with in vitro high-throughput RNAi and synthetic lethal interaction screens
- Accomplished external speaker and collaborator as evidenced by numerous invited presentations and publications
Nigel Pickersgill, BSc (Hons), C Biol, MRSB
Principal Scientific Advisor
As a principal scientific advisor, Nigel Pickersgill organizes and manages nonclinical safety programs within Charles River Safety Assessment, ensuring that all activities are conducted in compliance with relevant regulatory requirements and in accordance with scientific objectives, standards, and ethical/professional values, as well as established priorities and practices of the customer.
He collaborates with pharmaceutical and biotechnology companies worldwide, advising on programs and study design and monitoring nonclinical regulatory packages. He regularly attends training courses and scientific meetings, including those on intranasal administration and intravenous infusion.
- 35 years of experience in CRO industry
- New chemical entities, new biological entities, new molecular entities, dermatology, vaccines, and adjuvants
- Design, management, and reporting at all stages of candidate development
- Contributor to numerous scientific publications (often concerning infusion models and new techniques)
- Frequent presenter at various meetings to share his experience in infusion and regulatory toxicology
- Member of the Royal Society of Biology, a Charted Biologist, and member of the Infusion Technology Organisation
Keith Sutton, PhD
With a BSc (Hons) in immunology and a PhD in virology, Keith Sutton is a biologist with over 20 years of specialist knowledge in the areas of molecular biology, physiology and immunology.
He has a broad familiarity with a range of model systems relevant to the development of cell and gene therapies, together with a deep understanding of analytical approaches and their application in a regulatory environment. Having worked in both commercial and academic environments across the UK, US, and Australia he has worked in multidisciplinary drug development teams with colleagues from a broad range of backgrounds and experience. His project management experience encompasses delivery by both internal and external relationships. Keith is a speaker at international conferences, has authored several primary research articles, many commentary review articles (including publications in Cell and Nature Cell Biology) and is co-author of a patent (Enkurin and the uses thereof).
- His broad experience in comparative physiology is regularly employed by clients and colleagues in relation to both assay development and the interpretation of toxicology findings on the basis of mode of action
- Broad experience with cell and gene therapies including viral and non-viral vectored gene therapies, gene editing technologies, stem cell therapies, CAR-Ts
- He also has experience in the design of PK and PD assessments for cell and gene therapies, mAbs, and ASOs
- Experience with analytical design and support of clinical programs for cell and gene therapy products
- He is the head of molecular biology at Charles River and a member of the Edinburgh site biosafety committee
Michael V. Templin, PhD, DABT
Michael Templin is a senior principal scientific advisor for both biotechnology and pharmaceutical drug development with expertise in the realms of toxicology, pharmacology, pharmacokinetics, and pharmacodynamics.
Specializing in numerous therapeutic areas including cancer, inflammation, cardiovascular, metabolic, and viral diseases, he has a proven track record for transitioning drug candidates from research into development. Mike uses his diverse scientific knowledge to guide clients’ nonclinical development programs and to advise on ways to strengthen and/or accelerate their nonclinical programs.
- More than 15 years in biotechnology and pharma and 5+ years in nonclinical CRO
- Lead/team member in nonclinical and early clinical programs for companies ranging from start-up biotechnology to mid-sized pharmaceutical companies
- Portfolio surveillance and in-licensing/out-licensing of candidates and therapeutic programs
- Development of oligonucleotides (antisense, siRNA, miRNA, mRNA), biologics (mAbs, ADCs, bi-specifics, etc.), proteins/peptides, and small molecules
- Interaction with regulatory authorities and government agencies, presentations at scientific meetings
- Member of the Society of Toxicology and the American College of Toxicology and a Diplomate of the American Board of Toxicology
- Course instructor at universities, CE programs, and drug development courses